The New York Times considered how the official end of the GLP-1 shortages is affecting patients — yo...
“The GLP-1 drug shortage is over. What’s next for the compounders?” asks Pharmaceutical Technology m...
APC, along with several other organizations, has been fighting hard to protect California firefighte...
Over the last few weeks, with the FDA declaring the end of the GLP-1 shortages, APC’s reporter hotli...
In "Zepbound copycats remain online despite FDA ban," it looks at ways some compounders are continui...
How will the new administration regulate weight-loss drugs? The truth is, we don't know yet. Forbes ...
Inside Health Policy covered our letter to FDA protesting the agency's recent (ridiculous) statement...
We’re pretty happy with Newsday’s coverage of how patients taking GLP-1 drugs will be affected by th...
The Wall Street Journal is looking past the FDA’s official ending of the GLP-1 shortages and into th...
The Royal Society of Chemistry's Chemistry World has a terrific piece on the ending of the semagluti...